CagriSema — my 2-week log, condensed into one table
CagriSema — my 2-week log, condensed into one table. I have gone back and forth on this for months.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 98.0% against a claimed 97.5%, and I posted it because the log needs entries.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
Is there any independent purity data on this compound that you have seen?
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.